<DOC>
	<DOCNO>NCT01012297</DOCNO>
	<brief_summary>This randomized phase III trial study gemcitabine hydrochloride , docetaxel , bevacizumab see well work compare gemcitabine hydrochloride , docetaxel , placebo treat patient advanced recurrent uterine leiomyosarcoma . Drugs use chemotherapy , gemcitabine hydrochloride docetaxel , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth tumor cell block blood flow tumor . It yet know whether gemcitabine hydrochloride docetaxel effective give without bevacizumab treat uterine leiomyosarcoma .</brief_summary>
	<brief_title>Gemcitabine Hydrochloride Docetaxel With Without Bevacizumab Treating Patients With Advanced Recurrent Uterine Leiomyosarcoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether addition bevacizumab fixed-dose rate gemcitabine-docetaxel reduces progression-free survival ( PFS ) event rate compare gemcitabine-docetaxel plus placebo patient advance recurrent uterine leiomyosarcoma ( LMS ) . SECONDARY OBJECTIVES : I . To determine objective response rate , measure RECIST , patient treat fixed-dose rate gemcitabine-docetaxel bevacizumab , compare objective response rate patient treat fixed-dose rate gemcitabine-docetaxel placebo . II . To determine addition bevacizumab combination gemcitabine docetaxel increase overall survival patient advance recurrent uterine LMS . III . To determine toxicity profile fixed-dose rate gemcitabine-docetaxel without bevacizumab patient population . IV . To bank formalin-fixed paraffin-embedded ( FFPE ) tumor tissue research . OUTLINE : This multicenter study . Patients stratify accord prior whole-pelvic radiotherapy ( yes v ) . Patients randomize 1 2 treatment arm . ARM I : Patients receive placebo IV 30-90 minute day 1 , gemcitabine hydrochloride IV 90 minute day 1 8 , docetaxel IV 60 minute day 8 . Patients also receive filgrastim subcutaneously ( SC ) day 9-15 pegfilgrastim SC day 9 10 . ARM II : Patients receive bevacizumab IV 30-90 minute day 1 , gemcitabine hydrochloride IV 90 minute day 1 8 , docetaxel IV 60 minute day 8 . Patients also receive filgrastim SC day 9-15 pegfilgrastim SC day 9 10 . In arm , course repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>Patients must advance recurrent uterine leiomyosarcoma document disease progression ; histologic confirmation original primary tumor require All patient must measurable disease define RECIST 1.1 ; measurable disease define least one lesion accurately measure least one dimension ( long diameter record ) ; lesion must &gt; = 10 mm measure CT , MRI caliper measurement clinical exam ; &gt; = 20 mm measure chest xray ; lymph node must &gt; = 15 mm short axis measure CT MRI Patient must least one `` target lesion '' use assess response protocol define RECIST 1.1 ; tumor within previously irradiate field designate `` nontarget '' lesion unless progression document biopsy obtain confirm persistence least 90 day follow completion radiation therapy Patients must GOG Performance Status 0 , 1 , 2 Patients must recover effect recent surgery , radiotherapy therapy Patients free active infection require antibiotic ( exception uncomplicated UTI ) Any hormonal therapy direct malignant tumor must discontinue least one week prior first day study treatment ; continuation hormone replacement therapy permit Platelet count great equal 100,000/mm^3 ANC count great equal 1,500/mm^3 Creatinine less equal 1.5 x institutional upper limit normal ( ULN ) , per NCI CTCAE Version 4.0 Grade 1 Bilirubin within normal range ( CTCAE Version 4 Grade 0 ) SGOT alkaline phosphatase less equal 2.5 x ULN , per CTCAE Version 4.0 Grade 1 ) SGOT le equal 2.5 x ULN , per CTCAE Version 4.0 Grade 1 Alkaline phosphatase less equal 2.5 x ULN , per CTCAE Version 4.0 Grade 1 Neuropathy ( sensory motor ) less equal Grade 1 per CTCAE Version 4.0 . No history transient ischemic attack ( TIA ) stroke CNS hemorrhage within past 6 month Urine protein creatinine ( UPC ) ratio must &lt; 1.0 gm ; UPC ratio &gt; = 1 , collection 24hour urine measurement urine protein recommend PT international normalize ratio ( INR ) = &lt; 1.5 PTT = &lt; 1.5 time institutional upper limit normal ( intherapeuticrange INR , usually 2 3 , patient stable dose therapeutic warfarin ) Patients must sign approve informed consent authorization permit release personal health information Patients must meet preentry requirement Patients childbearing potential must negative serum pregnancy test prior study entry practice effective form contraception Patients receive prior cytotoxic chemotherapy management uterine sarcoma ; patient receive prior VEGFpathway target agent bevacizumab , PTK787 , VEGFtrap , receive prior treatment multikinase inhibitor sorafenib sunitinib eligible Patients prior therapy docetaxel gemcitabine bevacizumab Patients history invasive malignancy , exception nonmelanoma skin cancer , carcinoma situ cervix , ductal carcinoma situ breast , exclude evidence malignancy present within last five year ; patient also exclude previous cancer treatment contraindicate protocol therapy Patients active bleed pathologic condition carry high risk bleeding , know bleed disorder , coagulopathy , tumor involve major vessel ; ( necessary use warfarin low molecular weight heparin permit , provide INR maintain therapeutic range approximately 23 ) Patients major surgery significant traumatic injury within 28 day prior study entry Patients history abdominal fistula perforation within past 12 month Patients current , serious , nonhealing wound , ulcer , bone fracture Patients history evidence upon physical examination CNS disease , include history primary brain tumor , history brain metastasis , seizure control standard medical therapy Patients know hypersensitivity Chinese hamster ovary cell product recombinant human humanize antibody Cardiovascular function ; specifically , patient may : Uncontrolled hypertension , define systolic &gt; 150 mm Hg diastolic &gt; 100 mm Hg patient history hypertension ; patient history hypertension enrollment study permit , patient must BP le equal 140/90 mmHg ; use blood pressure medication achieve maintain blood pressure control permit Myocardial infarction unstable angina within 6 month first date bevacizumab/placebo therapy New York Heart Association ( NYHA ) Grade II great congestive heart failure serious cardiac arrhythmia require medication ; woman receive prior treatment anthracycline ( include doxorubicin and/or liposomal doxorubicin ) ejection fraction &lt; 50 % exclude study Grade 1 , Category 2 great , peripheral vascular disease ; patient anything bad mild , symptomatic claudication exercise History cerebrovascular accident ( CVA , stroke ) , transient ischemic attack ( TIA ) subarachnoid hemorrhage within six month first date bevacizumab/placebo therapy History pulmonary embolism deep vein thrombosis past 6 month Patients , anticipation , invasive procedure define : Major surgical procedure , open biopsy significant traumatic injury within 28 day prior first date bevacizumab/placebo therapy Major surgical procedure anticipate course study . Minor surgical procedure ( i.e. , mediport insertion ) , fine needle aspirate , core biopsy within 7 day prior first date bevacizumab/placebo therapy Patients pregnant nursing</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>